Stanford Cancer Institute Directory
Stanford Cancer Institute Profiles
Showing 181 - 190 of 463
Professor (Research) of Medicine (Stanford Prevention Research Center/Cancer Institute) and, by courtesy, of Health Research and Policy (Epidemiology)
Dr. Hsing is a professor of medicine at Stanford University and a co-leader of the Population Sciences Program at Stanford Cancer Institute. A senior fellow for the Center for Innovation in Global Health at Stanford University, Dr. Hsing has conducted population-based epidemiological studies on four continents, including North and South America, Asia, Africa, and Europe. She is a leading expert in the epidemiology and etiology of prostate, hepatobiliary, and thyroid cancers as well as in hormonal carcinogenesis and circadian rhythm. Throughout her 22-year tenure at National Cancer Institute, Dr. Hsing developed extensive expertise in molecular epidemiology, global oncology, cancer prevention, and population-based studies in international settings. She has served on numerous committees and advisory boards, most recently as a member of the Editorial Board of Cancer Epidemiology, Biomarkers & Prevention and as an academic editor of PLOS ONE. She also has served as an adjunct professor in the Department of Epidemiology and the Department of Urology at the George Washington University in Washington, D.C., as well as in the Department of Public Health of Fu Jen Catholic University’s School of Medicine in Taiwan. Dr. Hsing has authored more than 270 peer-reviewed articles, written seven book chapters, and mentored over 50 post-doctoral fellows and scholars. Dr. Hsing currently serves as PI on the following funded projects: • A pilot study to assess the feasibility of building a population-based cancer registry in Accra, Ghana; • A study to assess patterns and trends of liver cancer in the Greater Bay area and in California and to project liver cancer burden in 20 years; • A pilot study in the Bay area to investigate non-viral factors of liver cancer; • A pilot study to investigate the clinical utility of ctNDA in post-treatment surveillance of liver cancer in Mongolia; • A whole genome sequencing study of aggressive thyroid cancer to identify novel prognostic factors; • A cohort study of 10,000 healthy individuals in Taiwan to investigate social and biochemical determinants of wellness (WELL Taiwan); • A cohort study of 10,000 healthy individuals in China to investigate social and biochemical determinants of wellness (WELL China); • A multiethnic cohort study of 550,000 individuals in Singapore to investigate social and biochemical determinants of wellness (WELL Singapore) She also serves as the Stanford PI of a consortium study of a genome-wide association study (GWAS) of prostate cancer in the African countries of Ghana, Senegal, Nigeria, and South Africa. More recently, her her work involves big data studies using such resources as the National Health Insurance Research Database, SEER-Medicare, and other large administrative claims and medical record databases to identify clinically relevant questions to help inform clinical practice.
Associate Professor of Radiology (Nuclear Medicine) at the Stanford University Medical Center
Dr. Iagaru is an Associate Professor of Radiology - Nuclear Medicine and the Chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford Health Care. He completed medical school at Carol Davila University of Medicine, Bucharest, Romania, and an internship at Drexel University College of Medicine, Graduate Hospital, in the Department of Medicine in Philadelphia. He began his residency at the University of Southern California (USC) Keck School of Medicine, Los Angeles, in the Division of Nuclear Medicine, where he was the chief resident. Dr. Iagaru finished his residency and completed a PET/CT fellowship at Stanford University's School of Medicine in the Division of Nuclear Medicine. His research interests include PET/MRI and PET/CT for early cancer detection; clinical translation of novel PET radiopharmaceuticals; peptide-based diagnostic imaging and therapy; and radioimmunotherapy. Since joining the faculty at Stanford in 2007, Dr. Iagaru has received several awards including the Society of Nuclear Medicine (SNM) 2009 Image of the Year Award; American College of Nuclear Medicine (ACNM) Mid-Winter Conference 2010 Best Essay Award; 2009, 2014 and 2015Western Regional SNM Scientist Award; 2011 SNM Nuclear Oncology Council Young Investigator Award; and a Stanford Cancer Center 2009 Developmental Cancer Research Award in Translational Science. Dr. Iagaru presented more than 100 abstracts at national and international meetings and published more than 100 papers in peer-reviewed journals, as well as 7 book chapters.
C. F. Rehnborg Professor in Disease Prevention in the School of Medicine and Professor, by courtesy, of Statistics and of Biomedical Data Science
C.F. Rehnborg Chair in Disease Prevention at Stanford University, Professor of Medicine, Professor of Health Research and Policy, Professor (by courtesy) of Biomedical Data Science, Professor (by courtesy) of Statistics; co-Director, Meta-Research Innovation Center at Stanford; Director of the PhD program in Epidemiology and Clinical Research. Born in New York City in 1965 and raised in Athens, Greece. Valedictorian (1984) at Athens College; National Award of the Greek Mathematical Society (1984); MD (top rank of medical school class) from the National University of Athens in 1990; also received DSc in biopathology from the same institution. Trained at Harvard and Tufts (internal medicine and infectious diseases), then held positions at NIH, Johns Hopkins and Tufts. Chaired the Department of Hygiene and Epidemiology, University of Ioannina Medical School in 1999-2010 (tenured professor since 2003). Adjunct faculty for Tufts University since 1996 (professor rank since 2002), Director (2008-2010) of the the Center for Genetic Epidemiology and Modeling; also adjunct professor of epidemiology at Harvard School of Public Health and visiting professor of epidemiology and biostatistics at Imperial College. Member of the executive board of the Human Genome Epidemiology Network and Senior Advisor on Knowledge Integration at NCI/NIH (2012-6). Served as President, Society for Research Synthesis Methodology, and editorial board member of many leading journals (including PLoS Medicine, Lancet, Annals of Internal Medicine, JNCI, Science Translational Medicine, Clinical Chemistry, Molecular and Cellular Proteomics, AIDS, IJE, JCE, Clinical Trials, and PLoS ONE, among others) and as Editor-in-Chief of the European Journal of Clinical Investigation (2010-now). Delivered ~500 invited and honorary lectures. Recipient of many awards (e.g. European Award for Excellence in Clinical Science , Medal for Distinguished Service, Teachers College, Columbia University , Chanchlani Global Health Award ). Inducted in the Association of American Physicians (2009), European Academy of Cancer Sciences (2010) American Epidemiological Society (2015), and European Academy of Sciences and Arts (2015). Honorary titles from FORTH (2014) and Ioannina (2015) and honorary doctorates from Rotterdam (2015) and Athens (2017). Multiple honorary lectureships (Caltech, Oxford, LSHTM, Yale, U Utah, UConn among others). The PLoS Medicine paper on “Why most published research findings are false” has been the most-accessed article in the history of Public Library of Science (2.5 million hits). Author of 7 literary books in Greek, two of which (“Toccata for the Girl with the Burnt Face” (Kedros 2012) and “Variations on the Art of the Fugue and a Desperate Ricercar” (Kedros 2014)) were shortlisted for best book of the year Anagnostis awards. Brave Thinker scientist for 2010 according to Atlantic, “may be one of the most influential scientists alive”. Author of ~1000 papers in peer-reviewed journals, 67% of papers as single/first/last author. Highly Cited Researcher according to Thomson Reuters in both Clinical Medicine and in Social Sciences. Citation indices: h=163, m=7 per Google Scholar (h=134 per ISI and Scopus). Current citation rates: >2,700 new citations per month per Google Scholar, >1,400 new citations per month per Scopus or Web of Knowledge. Current citation rates suggest that I am among the 20 scientists worldwide who are currently the most commonly cited, perhaps also the currently most-cited physician. This probably only proves that citation metrics are highly unreliable, since I estimate that I have been rejected over 1,000 times in my life. Regardless, I consider myself privileged to have learned and to continue to learn from interactions with students and young scientists (of all ages) from all over the world and I love to be constantly reminded that I know next to nothing.